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Abstract: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system
(CNS). T helper (Th) 17 lymphocytes play a role in the pathogenesis of MS. Indeed, Th17 cells are
abundant in the cerebrospinal fluid and peripheral blood of MS patients and promote pathogenesis in
the mouse model of MS. To gain insight into the function of Th17 cells in MS, we tested whether Th17
cells polarized from naïve CD4 T cells of healthy donors and MS patients display different features.
To this end, we analysed several parameters that typify the Th17 profile during the differentiation
process of naïve CD4 T cells obtained from relapsing-remitting (RR)-MS patients (n = 31) and healthy
donors (HD) (n = 28). Analysis of an array of cytokines produced by Th17 cells revealed that expression
of interleukin (IL)-21, tumour necrosis factor (TNF)-β, IL-2 and IL-1R1 is significantly increased in
Th17 cells derived from MS patients compared to healthy donor-derived cells. Interestingly, IL-1R1
expression is also increased in Th17 cells circulating in the blood of MS patients compared to healthy
donors. Since IL-2, IL-21, TNF-β, and IL-1R1 play a crucial role in the activation of immune cells, our
data indicate that high expression of these molecules in Th17 cells from MS patients could be related
to their high inflammatory status.
Keywords: multiple sclerosis; T helper -17 cells; interleukin-1 receptor; interleukin-2; interleukin-21;
tumour necrosis factor-beta
1. Introduction
Multiple sclerosis (MS) is a disease affecting the central nervous system (CNS), and involves
inflammation and neurodegeneration [1,2]. The symptoms of MS are due to the migration
of inflammatory immune cells into the CNS and the destruction of myelin, which causes
neuroinflammation and neurodegeneration [3]. In MS patients, pathogenic lymphocytes express
molecules that facilitate their transit through the blood-brain barrier (BBB), which is normally
precluded [2]. Once lymphocytes have penetrated the CNS, they proliferate and release cytokines,
thus contributing to a complex inflammatory response that leads to myelin damage [4].
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In particular, T helper (Th) 17 cells, a subtype of lymphocytes differentiated from naive CD4+
T cells and producing interleukin (IL)-17, are considered potent inflammatory effectors in MS [5,6].
Importantly, the pathogenic potential of Th17 cells does not rely exclusively on the production of IL-17,
and it is believed that a combination of inflammatory factors is required [6]. For instance, Th17 cells
express high levels of the C-C chemokine receptor 6 (CCR6) on the cell surface [7] that binds the C-C
chemokine ligand 20 (CCL20) expressed by both Th17 cells and the vascular endothelium of the BBB,
thus enabling the entry of Th17 cells into the encephalic compartment through the choroid plexus [8].
Moreover, Th17 cells produce other inflammatory cytokines, such as tumour necrosis factor (TNF)-α,
IL-21, IL-22, which are likely to contribute to their pathogenicity [9,10].
Differentiation of Th17 cells requires IL-1β, IL-6, IL-23, and transforming growth factor (TGF)-β [11],
which promote the expression of the RAR-related orphan receptor (ROR)-γt transcription factor and
determine the activation of the Th17 cell lineage-specific differentiation program [12]. Among the Th17
polarizing cytokines, IL-1β is considered crucial for the inflammatory properties of human Th17 cells,
due to its inhibitory role in IL-10 production [11,13]. In mice, IL-1β, together with IL-23, is implicated
in the enhancement of Th17 cell differentiation primed by TGF-β and IL-6 [14], and for acquisition of a
pathogenic phenotype by Th17 cells [9,15].
IL-1β binds a complex formed by its receptor (IL-1R1) and the IL-1R accessory protein (IL-1RAcP),
thus triggering a signal transduction cascade involving the adaptor protein MYD88 and induction
of specific inflammatory genes [16,17]. This pathway plays a key role in experimental autoimmune
encephalomyelitis (EAE), the mouse model of MS, as a knockout of the IL-1R1 or the MYD88 gene in
mice, which significantly ameliorates disease-associated phenotypes [18]. Importantly, their function in
EAE seem to be related to Th17 cells, as ablation of IL-1R1 signalling strongly suppressed Th17-mediated
EAE in cell transplantation experiments [15]. Moreover, it has been recently demonstrated that IL-1R1
expression is higher in CD4 T cells derived from MS patients in comparison to those from healthy
donors [19].
In this retrospective study, we analysed expression of IL-1R1 and other Th17 typical features in
Th17 cells derived from MS patients and healthy donors. In fact, a systematic study investigating the
differentiation process of human Th17 cells in MS patients has never been performed. We hypothesised
that Th17 cell differentiation is altered in MS patients, thus leading to the acquisition of pathogenic
features that contribute to persistent inflammation in MS.
2. Methods
2.1. MS Subjects
Patients diagnosed with relapsing–remitting (RR)-MS (n = 31) according to the revised McDonald
diagnostic criteria [20] were enrolled in the study. The demographic and clinical characteristics of
the RR-MS patients included in the study for blood sampling are described in Table 1. All patients
included in the blood study did not take immunomodulant or immunosuppressive compounds for at
least 2 months before recruitment.
Table 1. Demographic and clinical characteristics of MS subjects at the time of experiment.
Number 31
Gender (male/female) 5/26
Age (years) 43 ± 9.7
EDSS 2 ± 1.35
MRI (gadolinium +/−) 7/24
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As controls, we used blood from age and gender matched individuals (n = 28) without inflammatory
or degenerative diseases of the central or peripheral nervous system. These subjects were volunteers
that underwent blood testing.
Approval by the ethics committee of the IRCCS Neuromed, Pozzilli (IS), Italy and San Camillo
Hospital, Rome (Italy), and written informed consent in accordance with the Declaration of Helsinki
from all participants, were obtained before the study was initiated.
2.2. Purification of Naive CD4+ T Lymphocytes from Adult blood
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll gradient centrifugation
(GE Healthcare, Little Chalfont, UK) from whole blood. For sorting of IL-1R1+ cells, PBMC were stained
with anti-human CD4-FITC (Miltenyi, Bergisch Gladbach, Germany) (1:100) and anti-human IL-1R1-PE
(RnD, Minneapolis, MN, USA) (1:20) and sorted by a MoFlo high speed cell sorter (Beckman Coulter,
Atlanta, GA, USA). For sorting of naive CD4 T cells, the cells were stained with the anti-CD4-FITC
(Miltenyi) (1:100), and CD4+ T Lymphocytes were purified by immunomagnetic selection, using
the anti-FITC isolation kit (Miltenyi). After the isolation, the cells were stained with anti-CD4 FITC
(Miltenyi) (1:100), anti-CD45RA BV421 (BD Biosciences, San Jose, CA, USA) (1:60), anti-CD45RO PE
(BD Biosciences) (1:30), anti-CD27 APC (Miltenyi) (1:60), and CD4+ naive T cells were sorted by MoFlo
high speed cell sorter (Beckman Coulter) as CD4high, CD45RAhigh, CD45RO- and CD27+. Sorted cells
had a purity of over 97%, measured by flow cytometry (data not shown).
2.3. Th Cell Differentiation Assay
Naive CD4+ T cells were cultured in 96-well round-bottomed plates (Corning, New York City,
NY, USA) at a density of 5 × 104 per well in X-VIVO 15 serum-free medium (Lonza, Walkersville, MD,
USA) in the presence of Dynabeads CD3-CD28 T cell expander (one bead per cell; Life Technologies,
Carlsbad, CA, USA) and indicated cytokines: IL-1β (10 ng/mL), IL-6 (20 ng/mL), TGF-β (1 ng/mL) and
IL-23 (100 ng/mL) (Miltenyi) for Th17 differentiation, as previously described [11,21]. After 5–6 days,
cells were harvested and stained for flow cytometry analysis, or extensively washed, counted, and
re-stimulated 1 × 106 cells/mL with Dynabeads CD3-CD28 T cell expander (one bead per cell) for 24 h
for cytokine quantification.
2.4. Flow Cytometry Analysis
Cells were stained with the following antibodies: anti-human ROR-γt-BV421 (BD Biosciences)
(1:20), anti-human CCR6-Alexa 647 (BD) (1:20), anti-human IL-1R1-PE (RnD) (1:20), anti-human
CD4-PECy7 (Beckman Coulter) (1:100), CD161-BV421 (Biolegend, San Diego, CA, USA) (1:40),
anti-human CD3 FITC (Miltenyi) (1:100). Samples were analysed using Cytoflex cytometer (Beckman
Coulter, Brea, CA, USA) and analysed using FlowJo-10 software version 10.3.0.
2.5. Cytokine Quantification
IL-17 in culture supernatant was quantified with an enzyme-linked immunosorbent assay (ELISA)
kit (RnD Systems, Minneapolis, MS, USA). Other cytokines (IL-2, IL-4, IL-5, IL-7, IL-8, IL-9, IL-10, IL-13,
IL-15, IL-21, IL-22, TNF-α, TNF-β, GM-CSF, IFN-γ, PDGF-AA, PDGF-AB/BB, CCL20) were quantified
using a magnetic bead panel (Millipore, Burlington, MA, USA), following the manufacturer’s protocol,
and analysed by Luminex.
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2.6. Statistical Analysis
For pair-wise comparisons of different conditions from the same donors or different donors, we
used a parametric two-tailed paired or unpaired t test, respectively. One-way ANOVAs was performed
to analyse the main effects of two conditions on the dependent variables and their interactions. Data
were presented as mean ± standard error (s.e.m). The p values (p) of 0.05 or less, were considered
statistically significant.
3. Results
3.1. IL-21 Production by Th17 Cells Is Increased in MS Patients Compared to Healthy Donors
Given the pathogenic role played by Th17 cells in MS, we hypothesized that Th17 cells differentiated
from MS patients and healthy donors would display a differential cytokine profile. To test this
hypothesis, naive CD4+ T cells from healthy donors and RR-MS patients were differentiated in Th17
cells under in vitro culture conditions. We analysed the cytokines produced by polarized Th cells after
6 days of culture. First, we measured the production of ten Th profile-associated cytokines for the Th1,
Th17 and Th2 subsets. Interferon (IFN)-γ, the prototypical Th1 cytokine, and IL-22, whose expression
pattern is closely related to that of IFN-γ [10], are included in the Th1 category (Figure 1A). The Th17
class of cytokines includes IL-17, the prototypical Th17 cytokine, IL-21, produced by Th17 cells and
involved in the autocrine enhancement of their differentiation, and CCL20, the ligand of CCR6, which
enables the entry of Th17 cells into the CNS (Figure 1B). A third set of cytokines produced mainly
in Th2 conditions includes IL-4, IL-5, IL-13, IL-9, and IL-10 (Figure 1C). As expected, we observed
the upregulation of Th17 cytokines and IFN-γ in Th17 compared to Th0 conditions, in both healthy
donors and MS patients (Figure 1A,B). Typical Th2 cytokines (IL-4, IL-5, IL-13) were decreased in
Th17 compared to Th0 conditions, while IL-9 and IL-10 were produced by Th17 cells, although not
upregulated compared to Th0 (Figure 1C). While most of these cytokines were similarly modulated
in MS and healthy donors (Figure 1A–C), we found that the expression of IL-21 was significantly
higher in MS compared to healthy donors (Figure 1B), indicating a possible role for this cytokine in
Th17-related MS pathogenesis.
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antiCD3-antiCD28 alone (Th0) or antiCD3-antiCD28 + TGF-β, IL-6, IL-23 and IL-1β (Th17). At 5 days 
of differentiation the levels of typical cytokines of Th1 (A), Th17 (B), and Th2 (C) cells were analysed 
by multiplex assay (Luminex) in cell supernatants (* p < 0.05; ** p < 0.01; *** p < 0.001). 
3.2. Production of Cytokines Involved in Inflammation and T Cell Activation are Increased in Th17 Cells 
from MS Patients 
To investigate other features related to Th17 cells, we analysed the production of additional 
inflammatory cytokines that are typically produced by activated lymphocytes, including TNF-α, IL-
8, and TNF-β, in Th17 cells differentiated from MS patients or healthy donors. We found that in MS 
patients, the production of TNF-α and β is significantly higher in Th0 and Th17 cells, respectively 
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Figure 1. IL-21 production by Th17 cells is increased in MS patients compared to healthy donors.
Naive CD4 T cells from healthy donors (HD) and mult ple sclerosis (MS) patients were cultured with
antiCD3-antiCD28 alone (Th0) or antiCD3-antiCD28 + TGF-β, IL-6, IL-23 and IL-1β (Th17). At 5 days
of differentiation the levels of typical cytokines of Th1 (A), Th17 (B), and Th2 (C) cells were analysed by
multiplex assay (Luminex) in cell supernatants (* p < 0.05; ** p < 0.01; *** p < 0.001).
3.2. Production of Cytokines Involved in Inflammation and T Cell Activation Are Increased in Th17 Cells from
MS Patients
To investigate other features related to Th17 cells, we analysed the production of additional
inflammatory cytokines that are typically produced by activated lymphocytes, including TNF-α, IL-8,
and TNF-β, in Th17 cells differentiated from MS patients or healthy donors. We found that in MS
patients, the production of TNF-α and β is significantly higher in Th0 and Th17 cells, respectively
(Figure 2A). The production of IL-8, although more highly induced in Th17 compared to Th0 cells, was
not differentially modulated in MS patients compared to healthy donors.
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Figure 2. Production of cytokines involved in inflammation and T cell activation are increased in
Th17 cells from MS patients. Naive CD4 T cells from healthy donors (HD) and multiple sclerosis (MS)
patients were cultured with antiCD3-antiCD28 alone (Th0) or antiCD3-antiCD28 + TGF-β, IL-6, IL-23
and IL-1β (Th17). At 5 days of differentiation the levels of inflammatory cytokines (A), cytokines
involved in T cell expansion (B), and growth factors (C) were analysed by multiplex assay (Luminex)
in cell supernatants (* p < 0.05; ** p < 0.01; *** .001; ** p < . 001).
Next, we analysed the production of three cytokines belonging to the common gamma-chain
family, IL-2, IL-7, and IL-15, involved in regulating the expansion and activation of all T cell subsets.
We observed that IL-2 is upregulated in both Th0 and Th17 cells from MS patients, whereas IL-7 is
upregulated only in Th0 from MS patients and IL-15 is not modulated (Figure 2B). Given the role of
IL-2 and IL-7 in T cell proliferation, these findings support the hypothesis of systemic T cell activation
in MS patients.
To expand our analysis, we also tested expression of growth factors produced by T lymphocytes,
such as platelet-derived growth factor (PDGF)-AA and AB/BB, and granulocyte-macrophage
colony-stimulating factor (GMCSF). We observed that PDGF, either composed by subunit AA, AB or
BB, is upregulated in Th17 cells, while an opposite trend was found for GM-CSF. However, both growth
factors are not differentially modulated in MS compared to healthy donor Th17 cells (Figure 2C).
3.3. Th17 Cells Differentiated from MS Patients Express Higher IL-1R1 Than Those Differentiated from
Healthy Donors
To address whether the acquisition of typical features of Th17 cells were differentially modulated
in MS patients compared to healthy donors, we analysed the expression of the transcription factor
ROR-γt, a master regulator of both mouse [12] and human Th17 cell differentiation [11,22], CCR6 [23]
and IL-1R1 [15], which are not found in Th1 and Th2 cells, and are considered hallmarks of Th17
cells. This analysis revealed that ROR-γt and CCR6 are upregulated in Th17 cells from all individuals
with no differences between cells obtained from MS patients and healthy donors (Figure 3A,B).
In contrast, Th17 cells polarized from MS patients expressed significantly higher levels of IL-1R1
than corresponding Th17 cells polarized from healthy donors (Figure 3C). However, no significant
differences were observed in cells obtained from MS patients in either the active or inactive phase of
the RR disease (Supplementary Materials, Figure S1), according to the presence (Gadolinium+) or
the absence (Gadolinium-) of contrast-enhancing lesions detected by magnetic resonance imaging.
This suggested that IL-1R1 expression on the Th17 cell surface was not influenced by the acute stage of
inflammation. To determine whether IL-1R1 expression was dependent of a specific Th17-promoting
cytokine, we removed them from the polarization medium. This analysis revealed that, similar to
other Th17 molecules11, IL-1R1 expression in Th17 cells is mediated by the synergy between TGF-β
and proinflammatory cytokines IL-1β, IL-6, and IL-23, although none of them exhibit a predominant
role (Supplementary Materials, Figure S2).
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Figure 3. Th17 cells differentiated from MS patients express higher IL-1R1 than those differentiated
from healthy donors. Naive CD4 T cells from healthy donors (HD) and multiple sclerosis (MS) patients
were cultured with antiCD3-antiCD28 alone (Th0) or antiCD3-antiCD28 + TGF-β, IL-6, IL-23 and IL-1β
(Th17). At 5 days of differentiation cells were stained with specific antibodies against RORγt (A), CCR6
(B), and IL-1R1 (C) and analysed by flow cytometry. Graphs represent the results of independent
experiments. (* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.).
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3.4. IL-1R1+ Cells in the Blood Are Th17 Cells and Are Increased in MS Patients Compared to Healthy Donors
To investigate the physiological relevance of the increased IL-1R1 expression in Th17 cells
differentiated from MS patients in vitro, we sorted blood memory CD4+ T cells for positivity or
negativity in IL-1R1 expression. We found that CD4+ IL-1R1+ cells produced more IL-17 than CD4+
cells not expressing IL-1R1 (Figure 4A). This result indicates that IL-1R1 expression is also associated
to IL-17-producing cells in vivo. In order to investigate whether Th17 cells are different in the blood of
MS patients and healthy individuals, we analysed the frequency of circulating IL-1R1+ cells within
the CD4+ CD161+ CCR6+ cell population, which corresponds to the population of memory Th17
cells [24,25]. Importantly, expression of IL-1R1 in the in vivo-differentiated Th17 cells was higher in MS
patients compared to healthy donors (Figure 4B), indicating that mechanisms leading to overexpression
of IL-1R1 in MS also occur in vivo.
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Figure 4. IL-1R1+ cells in the blood are Th17 cells and are increased in MS patients compared to healthy
donors. Blood memory cells sorted as CD4+ IL-1R1+ and CD4+ IL-1R1- cells (gating strategy in the
left panel) were stimulated with antiCD3-antiCD28 for 24h. Supernatants were then analysed for
IL-17 production by ELISA (A). Peripheral blood mononuclear cells from healthy donors (HD) and
multiple sclerosis (MS) patients were stained with specific antibodies to analyse the frequency of CD3+
CD4+ CCR6+ CD161+ IL-1R1+ cells by flow cytometry (B). Graphs represent the results of independent
experiments. (* p < 0.05; ** p < 0.01).
4. Discussion
In this study, systematic analysis of the typical features of Th17 cells revealed that cells derived
from MS patients display higher expression of IL-1R1 compared to Th17 cells derived from healthy
donors, and indicated that the corresponding higher expression of IL-1R1 previously observed in
MS [19] patients is specifically associated to Th17 cells. Furthermore, we identified other inflammatory
molecules that were differentially expressed that may contribute to the pathogenicity of Th17 cells
in MS.
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In fact, the analysis of a broad array of cytokines produced by Th17 cells in MS patients and
healthy donors revealed that IL-21 is significantly upregulated in MS patients compared to healthy
donors. This result is consistent with the high frequency of IL-21-producing T cells reported in both
active and chronic parenchymal lesions of MS brain [26], and increased levels of IL-21 induced by
anti-CD28 in CD4 from MS patients [27].
IL-21, similarly to IL-6 and IL-23, activates a signalling pathway involving STAT3, which directly
binds the IL-17 and IL-21 promoters [28], thus contributing to the sustainment of Th17 lineage
commitment [29]. However, IL-21 is also the most potent inducer of plasma-cell differentiation
in vitro [30], and provides help to B cells [31]. Recently it has been reported that the B-T cell interaction
plays a crucial pathogenic role in MS [32], which could be mediated by IL-21. Considering that MS
involves infiltration of both T and B cells in parenchymal demyelinating lesions, and in lymphoid
aggregates in the meninges [33,34], increased IL-21 levels produced by Th17 cells could play a critical
role in MS.
Our study also revealed that TNF-β, known as lymphotoxin-alpha (LTA), is upregulated in Th17
cells from MS patients, confirming previous observations showing that PBMC from RR-MS patients
had increased expression of LTA [35]. Similar to LTA, which is involved in the regulation of cell
survival and proliferation [36], other cytokines important for these functions in T cells, such as IL-2 and
IL-7, are upregulated in MS, suggesting that they may synergize to promote T cell expansion during
MS. In particular, IL-2 is significantly upregulated in cells derived from MS patients in both Th0 and
Th17 conditions. These results are in agreement with the observed increase in IL-2 levels in the serum
of patients with active MS [37], suggesting that the effector Th17 cells contribute to IL-2 production
in MS. In fact, T regulatory cells, known to suppress effector immune functions, from subjects with
RR-MS had impaired proliferation and reduced IL-2 secretion [38].
Another interesting finding of our study is that Th17 cells produce IL-8 and PDGF. Although
they were not modulated in MS versus healthy donors, IL-8 and PDGF were not previously known
to be produced by Th17 cells and are not typically considered Th cytokines. IL-8 plays an important
role in inflammation due to its high neutrophil-attracting capacity [39], and could synergize with
IL-17 in exerting this function. PDGF, which can be composed of two A subunits (PDGF-AA), two
B subunits (PDGF-BB), or one of each (PDGF-AB) [40,41], plays a significant role in blood vessel
formation. However, whether the production of PDGF contributes or not to the pathogenic functions
of Th17 cells in MS will require direct investigation.
Overall, the molecules upregulated in Th17 cells from MS patients could be related to their high
sensitivity to IL-1β, one of the most important Th17-regulating cytokine. In fact, in the same set
of experiments, IL-1R1 is significantly upregulated in MS patients, as previously demonstrated at
transcriptional level in naïve and memory CD4 T cells, and in vitro differentiated Th17 cells [19].
We further analysed the expression of IL-1R1 on memory Th17 cells, which we found were
significantly increased in MS patients. Previous comparative analysis on memory cells from MS and
healthy donors was performed in Th1/Th17 cells, and revealed a reduced transcriptional expression
of inflammatory factors, such as IFNG, CCL3, CLL4, and GZMB [42]. However, a broader analysis
at protein level of Th17 and Th1/17 subsets isolated from MS patients may help to identify more
disease-related features.
Our results indicated that IL-1R1 is upregulated at protein level in Th17 cells obtained from both
in vitro and in vivo differentiated CD4 T cells of MS patients, and that IL-1R1 signalling is a critical step
in the regulation of human Th17 cells in MS. In fact, it is already known that the IL-1β/axis is important
for differentiation of naive CD4 T cells into Th17 cells [11,14]. Recently it has been demonstrated that
IL-1β is also crucial for induction of IL-17A by memory CD4 T cells in the absence of T cell receptor
(TCR) engagement, introducing a TCR-independent innate-like pathogenic role of Th17 cells mediated
by IL-1β/IL1R1 signalling [43].
The relevance of IL-1R1 in MS is supported by previous results reporting that IL-1R1-deficient
mouse T cells developed a delayed and less severe EAE, and a lower percentage of IL-17 producing
Cells 2019, 8, 533 10 of 12
cells in the inflamed CNS compared to wild type mice15. In conclusion, our study identifies IL-21,
IL-2, TNF-β, and IL-1R1, as molecules likely involved in the mechanisms conferring pathogenicity to
human Th17 cells and opens another perspective on the use of these molecules as therapeutic targets
or biomarkers of MS disease.
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